Eton Pharmaceuticals, Inc.

NasdaqGM:ETON Stock Report

Market Cap: US$337.2m

Eton Pharmaceuticals Management

Management criteria checks 4/4

Eton Pharmaceuticals' CEO is Sean Brynjelsen, appointed in Jun 2017, has a tenure of 7.5 years. total yearly compensation is $1.75M, comprised of 33.9% salary and 66.1% bonuses, including company stock and options. directly owns 4.16% of the company’s shares, worth $14.03M. The average tenure of the management team and the board of directors is 2.2 years and 7.3 years respectively.

Key information

Sean Brynjelsen

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage33.9%
CEO tenure7.5yrs
CEO ownership4.2%
Management average tenure2.2yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

CEO Compensation Analysis

How has Sean Brynjelsen's remuneration changed compared to Eton Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

US$913k

Dec 31 2023US$2mUS$592k

-US$936k

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$234k

Mar 31 2023n/an/a

-US$6m

Dec 31 2022US$2mUS$570k

-US$9m

Sep 30 2022n/an/a

-US$9m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$2mUS$542k

-US$2m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$2mUS$476k

-US$28m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$2mUS$410k

-US$18m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$493kUS$332k

-US$37m

Sep 30 2018n/an/a

-US$18m

Dec 31 2017US$654kUS$172k

-US$13m

Compensation vs Market: Sean's total compensation ($USD1.75M) is about average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

CEO

Sean Brynjelsen (52 yo)

7.5yrs

Tenure

US$1,747,045

Compensation

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...

Leadership Team

NamePositionTenureCompensationOwnership
Sean Brynjelsen
President7.5yrsUS$1.75m4.16%
$ 14.0m
James Gruber
CFO, Treasurer & Secretary2.7yrsUS$785.14k0.049%
$ 164.5k
David Krempa
Chief Business Officer1.8yrsUS$719.08k0.081%
$ 271.4k
Danka Radosavljevic
Senior Vice President of Quality & Operationsless than a yearno datano data
Scott Grossenbach
Vice President of Sales Operationsno datano datano data
Kevin Guthrie
Executive VP of Commercial Operations2.9yrsno datano data
Ipek Erdogan-Trinkaus
Chief Commercial Officerno datano datano data

2.2yrs

Average Tenure

52yo

Average Age

Experienced Management: ETON's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sean Brynjelsen
President7.5yrsUS$1.75m4.16%
$ 14.0m
Paul Maier
Independent Director7.3yrsUS$129.50k0.23%
$ 779.7k
Charles Casamento
Independent Director7.5yrsUS$126.90k0.26%
$ 892.9k
Norbert Riedel
Independent Chairman7.3yrsUS$155.50k0.23%
$ 779.7k
Jennifer Adams
Independent Director3.8yrsUS$119.10kno data

7.3yrs

Average Tenure

66yo

Average Age

Experienced Board: ETON's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 07:53
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eton Pharmaceuticals, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Chase KnickerbockerCraig-Hallum Capital Group LLC
Swayampakula RamakanthH.C. Wainwright & Co.